Hyperion Therapeutics Announces Extension of Action Date for Ravicti™ NDA to January 23, 2013  
9/6/2012 9:41:03 AM

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that it has received a communication from the U.S. Food and Drug Administration (FDA) extending the Prescription Drug User Fee Act (PDUFA) action date for its New Drug Application (NDA) for Ravictiâ„¢ (glycerol phenylbutyrate) by three months to January 23, 2013. The FDA extended the action date to provide time for a full review of the submission. Such extensions are standard and are provided for by regulation when additional information is submitted within three months of a PDUFA action date.